Influence of Sokal, Hasford, EUTOS scores and pharmacogenetic factors on the complete cytogenetic response at 1 year in chronic myeloid leukemia patients treated with imatinib

被引：18
|
作者：
Francis, Jose [1 ]
Dubashi, Biswajit [2 ]
Sundaram, Rajan [1 ]
Pradhan, Suresh Chandra [1 ]
Chandrasekaran, Adithan [3 ]
机构：
[1] JIPMER, Dept Pharmacol, Pondicherry 605006, India
[2] JIPMER, Dept Med Oncol, Pondicherry 605006, India
[3] JIPMER, Dept Clin Pharmacol, Pondicherry 605006, India
来源：
MEDICAL ONCOLOGY | 2015年 / 32卷 / 08期
关键词：
Imatinib mesylate; Cytogenetic response; Overall survival; Pharmacogenetics; STANDARD-DOSE IMATINIB; PROGNOSTIC DISCRIMINATION; MOLECULAR RESPONSES; FREE SURVIVAL; CML PATIENTS; PHARMACOKINETICS; RESISTANCE; POLYMORPHISMS; CHILDREN; PLASMA;
D O I：
10.1007/s12032-015-0665-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Imatinib mesylate is currently considered the first-line treatment for chronic myeloid leukemia (CML). Sokal, Hasford and EUTOS are the three major risk categorization scores available for CML patients. The present study aimed to explore the influence of three risk score, genetic polymorphisms of ABCB1, OCT1, ABCG2 and trough level concentration on complete cytogenetic response at 1 year and overall survival. The mean time period of follow-up was 53.05 months, and the overall survival was 94.6 %. The Sokal score (P 0.014), Hasford score (P 0.016) and MDR1 C3435T (P 0.001) tend to influence the overall survival in the patients. The patients who had better overall survival had early complete cytogenetic response (P 0.0003). The ABCG2 C421A was the covariate which had correlation with the complete cytogenetic response. A perceptive approach incorporating pharmacogenetic evaluation with major risk categorization score at the initial stage will help in ensuring better treatment success in CML patients treated with imatinib.
引用
收藏
页数：6
相关论文
共 50 条
  • [1] Influence of Sokal, Hasford, EUTOS scores and pharmacogenetic factors on the complete cytogenetic response at 1 year in chronic myeloid leukemia patients treated with imatinib
    Jose Francis
    Biswajit Dubashi
    Rajan Sundaram
    Suresh Chandra Pradhan
    Adithan Chandrasekaran
    Medical Oncology, 2015, 32
  • [2] Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy
    Xia, Leiming
    Qian, Wei
    Yang, Mingzhen
    Li, Qingsheng
    Liu, Fei
    Xie, Yanyan
    ONCOTARGETS AND THERAPY, 2015, 8 : 2485 - 2492
  • [3] EUTOS score predicts survival and cytogenetic response in patients with chronic phase chronic myeloid leukemia treated with first-line imatinib
    Tao, Zhonfei
    Liu, Bingcheng
    Zhao, Yaozhong
    Wang, Ying
    Zhang, Rongli
    Han, Mingzhe
    Zhang, Li
    Li, Chengwen
    Ru, Kun
    Mi, Yingchang
    Wang, Jianxiang
    LEUKEMIA RESEARCH, 2014, 38 (09) : 1030 - 1035
  • [4] Prognostic discrimination for early chronic phase chronic myeloid leukemia in imatinib era: comparison of Sokal, Euro, and EUTOS scores in Korean population
    Yahng, Seung-Ah
    Jang, Eun-Jung
    Choi, Soo-Young
    Lee, Sung-Eun
    Kim, Soo-Hyun
    Kim, Dong-Wook
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2014, 100 (02) : 132 - 140
  • [5] Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy?
    Harivenkatesh, Natarajan
    Kumar, Lalit
    Bakhshi, Sameer
    Sharma, Atul
    Kabra, Madhulika
    Velpandian, Thirumurthy
    Gogia, Ajay
    Shastri, Shivaram S.
    Gupta, Yogendra Kumar
    LEUKEMIA & LYMPHOMA, 2017, 58 (09) : 2218 - 2226
  • [6] Imatinib trough levels: a potential biomarker to predict cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia
    Natarajan, Harivenkatesh
    Kumar, Lalit
    Bakhshi, Sameer
    Sharma, Atul
    Velpandian, Thirumurthy
    Kabra, Madhulika
    Gogia, Ajay
    Biswas, Nihar Ranjan
    Gupta, Yogendra Kumar
    LEUKEMIA & LYMPHOMA, 2019, 60 (02) : 418 - 425
  • [7] Mean cell volume can be an early predictor for the cytogenetic response of chronic myeloid leukemia patients treated with imatinib?
    Song, Moo-Kon
    Chung, Joo-Seop
    Seol, Young-Mi
    Kim, Seong-Geun
    Shin, Ho-Jin
    Choi, Young-Jin
    Cho, Goon-Jae
    LEUKEMIA RESEARCH, 2009, 33 (11) : 1459 - 1462
  • [8] Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels
    Forrest, Donna L.
    Trainor, Shannon
    Brinkman, Ryan R.
    Barnett, Michael J.
    Hogge, Donna E.
    Nevill, Thomas J.
    Shepherd, John D.
    Nantel, Stephen H.
    Toze, Cynthia L.
    Sutherland, Heather J.
    Song, Kevin W.
    Lavoie, Julye C.
    Power, Maryse M.
    Abou-Mourad, Yasser
    Smith, Clayton A.
    LEUKEMIA RESEARCH, 2009, 33 (02) : 271 - 275
  • [9] Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients
    Seong, S. J.
    Lim, M.
    Sohn, S. K.
    Moon, J. H.
    Oh, S. -J.
    Kim, B. S.
    Ryoo, H. M.
    Chung, J. S.
    Joo, Y. D.
    Bang, S. M.
    Jung, C. W.
    Kim, D. H.
    Park, S. Y.
    Yoon, S. S.
    Kim, I.
    Lee, H. G.
    Won, J. H.
    Min, Y. H.
    Cheong, J. W.
    Park, J. S.
    Eom, K. S.
    Hyun, M. S.
    Kim, M. K.
    Kim, H.
    Park, M. R.
    Park, J.
    Kim, C. S.
    Kim, H. J.
    Kim, Y. K.
    Park, E. K.
    Zang, D. Y.
    Jo, D. Y.
    Lee, H. W.
    Yoon, Y. -R.
    ANNALS OF ONCOLOGY, 2013, 24 (03) : 756 - 760
  • [10] Early blastic transformation following complete cytogenetic response in a pediatric chronic myeloid leukemia patient treated with imatinib mesylate
    Morimoto, A
    Ogami, A
    Chiyonobu, T
    Takanashi, M
    Sugimoto, T
    Imamura, T
    Ishida, H
    Yoshihara, T
    Imashuku, S
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2004, 26 (05) : 320 - 322
12345